• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Engelson Erik T. exercised 574,666 shares at a strike of $0.82 and sold $657,306 worth of shares (634,666 units at $1.04), decreasing direct ownership by 72% to 23,282 units

    3/13/23 6:30:09 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LHDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Engelson Erik T.

    (Last) (First) (Middle)
    C/O LUCIRA HEALTH INC.
    1412 62ND ST

    (Street)
    EMERYVILLE CA 94608

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Lucira Health, Inc. [ LHDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and Chief Executive
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/03/2023 M 574,666 A $0.82 657,948 D
    Common Stock 03/03/2023 S 574,666 D $1.03 83,282 D
    Common Stock 03/03/2023 S 60,000 D $1.09 23,282 D
    Common Stock 46,400 I See Footnotes(1)
    Common Stock 191,705 I See Footnotes(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock $0.82 03/03/2023 M 574,666 (3) 04/09/2029 Common Stock 574,666 $0.00 0 D
    Explanation of Responses:
    1. The shares are held by the Elizabeth North Engelson Trust, dated January 17, 2001, for which Mr. Engelson serves as trustee.
    2. The shares are held by Epic Pacific, LLC, of which Mr. Engelson is a Member. Mr. Engelson disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
    3. The shares subject to the option are immediately exercisable. 1/48th of the shares subject to the option shall vest monthly over the four years from the vesting commencement date.
    Remarks:
    /s/ Erik Engelson 03/13/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LHDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LHDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LHDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Engelson Erik T. exercised 574,666 shares at a strike of $0.82 and sold $657,306 worth of shares (634,666 units at $1.04), decreasing direct ownership by 72% to 23,282 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 6:30:09 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Narido Richard Clavano sold $29,423 worth of shares (29,383 units at $1.00), decreasing direct ownership by 27% to 77,910 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 5:10:58 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Collins Kevin Walter sold $73,841 worth of shares (111,819 units at $0.66), decreasing direct ownership by 32% to 234,903 units

    4 - Lucira Health, Inc. (0001652724) (Issuer)

    3/13/23 5:09:40 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing

    Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,

    2/27/23 8:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

    EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p

    2/22/23 5:15:48 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAM

    New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt

    1/5/23 9:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    SEC Filings

    View All

    SEC Form 15-12G filed by Lucira Health Inc.

    15-12G - Lucira Health, Inc. (0001652724) (Filer)

    10/4/23 3:31:57 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership

    8-K - Lucira Health, Inc. (0001652724) (Filer)

    9/25/23 4:01:01 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form NT 10-Q filed by Lucira Health Inc.

    NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)

    8/15/23 4:00:25 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lucira Health downgraded by William Blair

    William Blair downgraded Lucira Health from Market Outperform to Market Perform

    5/4/21 6:46:28 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health downgraded by BofA Securities with a new price target

    BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00

    4/13/21 6:49:01 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    William Blair initiated coverage on Lucira Health

    William Blair initiated coverage of Lucira Health with a rating of Outperform

    3/8/21 8:22:19 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Financials

    Live finance-specific insights

    View All

    Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates

    EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care

    11/14/22 4:02:00 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health to Announce Third Quarter 2022 Financial Results

    EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg

    11/1/22 7:00:00 AM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates

    EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc

    8/15/22 4:01:00 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LHDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lucira Health Inc. (Amendment)

    SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)

    12/22/22 3:17:39 PM ET
    $LHDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care